Oncternal Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 11.4 million compared to USD 8.07 million a year ago. Basic loss per share from continuing operations was USD 4 compared to USD 3.2 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.179 USD | -5.28% | -6.47% | -23.73% |
May. 09 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.73% | 24.21M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022